Table 3. SUCRA values and ranking probabilities for VKA, DOAC, and LMWH – Unadjusted and Adjusted Network meta-analysis.

*Adjusted results are from a model with a 10% six-month risk of recurrent VTE in the VKA arm (efficacy), and a 5% six-month risk of major bleeding in the VKA arm (safety). Abbreviations: SUCRA – Surface under the cumulative ranking curve (higher values indicating a potentially better treatment), PrBest – Probability that the respective treatment is the best out of the three compared treatments (caution is warranted in not over-interpreting this measure due to its sensitivity to small and outlying studies), MeanRank - Mean of the distribution of ranking probabilities.

Analysis	Treatment	Recurrent VTE			Major Bleeding
		SUCRA	PrBest	MeanRank	SUCRA	PrBest	MeanRank
Unadjusted NMA	VKA	2.6	0.0%	2.9	39.1	9.7%	2.2
	DOAC	68.0	41.2%	1.6	84.6	79.0%	1.3
	LMWH	79.4	58.7%	1.4	26.2	11.3%	2.5
Adjusted NMA*	VKA	20.2	2.5%	2.6	52.0	13.4%	2.0
	DOAC	84.5	74.7%	1.3	89.7	84.1%	1.2
	LMWH	45.2	22.8%	2.1	8.2	2.5%	2.8